[1] 张俊雅, 温晓斐, 闫鹏,等. 原发性肝癌的介入治疗现状与进展. 现代生物医学进展, 2016, 16:5797-5800.
[2] 李庆, 曹苏娟, 龙文兴,等. 125I粒子植入术联合TACE治疗大肝癌的临床效果. 中国医药导报, 2016, 13:73-77.
[3] Hu C, Rai R, Huang C, et al. Structural and functional analyses of the mammalian TIN2-TPP1-TRF2 telomeric complex.Cell Res, 2017, 27:1485-1502.
[4] 丛文铭, 步宏, 陈杰,等. 原发性肝癌规范化病理诊断指南(2015年版). 解放军医学杂志, 2015, 21:833-839.
[5] Kudo M, Ueshima K, Kubo S, et al. Response Evaluation Criteria in Cancer of the Liver (RECICL) (2015 Revised version).Hepatol Res, 2016, 46:3-9.
[6] 李大林. TACE与TAICE两种方法治疗原发性肝癌的对比研究. 临床放射学杂志, 2017, 36:119-122.
[7] 郑家平,邵国良,罗君,等.CT引导下I~(125)粒子组织间植入治疗难治性肝癌.介入放射学杂志,2015,24:260-264.
[8] 赵相轩, 卢再鸣. 端粒酶活性抑制在癌症治疗中的作用研究进展. 现代肿瘤医学, 2017, 25:3178-3181.
[9] Kong X, Cruz GMS, Trinh SL, et al. Biphasic recruitment of TRF2 to DNA damage sites promotes non-sister chromatid homologous recombination repair.J Cell Sci, 2018,131:465-467.
[10] Bouhlel L, Ilie M, Signetti L, et al. Abstract 3230: The role of TRF2 on tumor progression in non-small cell lung cancer: potential modulating effect on myeloid cells. Cancer Res, 2016, 76:3230. |
